Amneal Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Amneal Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Amneal Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Amneal Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Amneal Pharmaceuticals Inc (Amneal) is a specialty pharmaceutical company that develops, manufactures and distributes essential medicines. The company offers generic and specialty pharmaceutical products. Amneal offers products in various dosage forms comprising liquids, sterile injectables, oral solids, powders, nasal sprays, inhalation and respiratory products, transdermal patches, ophthalmics, films, and topicals. Its brands include ONGENTYS, Rytary, Unithroid, Emverm, Lyvispah and Zomig, among others. Amneal sells its products to wholesalers, chain pharmacies, distributors, hospitals, and individual pharmacies. The company operates in the US, India and Ireland. Amneal is headquartered in Bridgewater, New Jersey, the US.
Headquarters
United States of America
Address
3rd Floor, 400 Crossing Boulevard, Bridgewater, New Jersey, 08807
Website
amneal.com
Telephone
1 908 9473120
No of Employees
8,500
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AMRX (NASD)
Revenue (2024)
$3.0B
8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
161.6%
(2024 vs 2023)
Market Cap*
$5.4B
Net Profit Margin (2024)
XYZ
157.2%
(2024 vs 2023)
* As of and is in US$
Amneal Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Specialty | Activella |
| Injectables | Albenza |
| Anthelmintics | Dexedrine |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In June, the company secured approval from the U.S. Food and Drug Administration for romidepsin injection solution, 27.5 mg/5.5 mL, supplied in single-dose, ready-to-use vials. |
| 2026 | Contracts/Agreements | In April, the company entered into an agreement to acquire a 100% of Kashiv BioSciences, LLC, a biopharmaceutical company. |
| 2026 | New Products/Services | In April, the company introduced bimatoprost ophthalmic solution 0.01%. |
Competitor Comparison
| Key Parameters | Amneal Pharmaceuticals Inc | Pfizer Inc | AbbVie Inc | Gilead Sciences Inc | Viatris Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Bridgewater | New York City | North Chicago | Foster City | Canonsburg |
| State/Province | New Jersey | New York | Illinois | California | Pennsylvania |
| No. of Employees | 8,500 | 75,000 | 57,000 | 17,000 | 30,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Paul M. Meister | Chairman | Executive Board | 2019 | 72 |
| Chirag Patel | President; Director; Co-Chief Executive Officer | Executive Board | 2019 | 58 |
| Chintu Patel | Director; Co-Chief Executive Officer | Executive Board | 2019 | 53 |
| Anastasios Konidaris | Chief Financial Officer; Executive Vice President | Senior Management | 2020 | 58 |
| Jason B. Daly | Chief Legal Officer; Executive Vice President; Secretary | Senior Management | 2025 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer